Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

4.725 -0.295 (-5.88%)
Streaming Delayed Price Updated: 12:49 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 957,772
Open 5.100
Bid (Size) 4.720 (5,300)
Ask (Size) 4.730 (800)
Prev. Close 5.020
Today's Range 4.720 - 5.160
52wk Range 1.285 - 5.660
Shares Outstanding 47,722,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Which stocks are moving on Wednesday? ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill

Performance

YTD
N/A
N/A
1 Month
+16.4%
+16.4%
3 Month
+51.9%
+51.9%
6 Month
+63.5%
+63.5%
1 Year
-14.1%
-14.1%

More News

Read More
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in Upcoming September Investor Conferences
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Narrows Loss in Fiscal Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
News headline image
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Via Benzinga
News headline image
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire

Frequently Asked Questions

Is Annexon, Inc. - common stock publicly traded?
Yes, Annexon, Inc. - common stock is publicly traded.
What exchange does Annexon, Inc. - common stock trade on?
Annexon, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Annexon, Inc. - common stock?
The ticker symbol for Annexon, Inc. - common stock is ANNX on the Nasdaq Stock Market
What is the current price of Annexon, Inc. - common stock?
The current price of Annexon, Inc. - common stock is 4.725
When was Annexon, Inc. - common stock last traded?
The last trade of Annexon, Inc. - common stock was at 01/02/26 12:49 PM ET
What is the market capitalization of Annexon, Inc. - common stock?
The market capitalization of Annexon, Inc. - common stock is 225.49M
How many shares of Annexon, Inc. - common stock are outstanding?
Annexon, Inc. - common stock has 225M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.